Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.52 |
| ▸ | PDE4A | P27815 | 2/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29079727 | 0.89 | GPR119 (0.55) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL275679 | 0.88 | GPR119 (0.54) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2773558 | 0.85 | GPR119 (0.58) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2764837 | 0.85 | GPR119 (0.55) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL13718678 | 0.82 | GPR119 (0.66) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL69206 | 0.81 | KDM1A (0.56) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL26210196 | 0.81 | TOP2A (0.51) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL1576020 | 0.81 | GPR119 (0.56) | GPR119 | |
| SCHEMBL29964750 | 0.81 | GPR119 (0.59) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL26128483 | 0.81 | KDM4E (0.48) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | GPR119 1816/4885PDE4D 3794/4885PDE4B 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.